University of Tasmania
Browse
152400 - AstraZeneca COVID-19 vaccine and Guillain- Barr acute accent e Syndrome in Tasmania.pdf (5.67 MB)

AstraZeneca COVID-19 vaccine and Guillain- Barr acute accent e Syndrome in Tasmania: a causal link?

Download (5.67 MB)
journal contribution
posted on 2023-05-21, 12:02 authored by Oo, Wai M, Giri, Pradeep, Aaron de SouzaAaron de Souza
The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other reported cases and discuss likely immunopathology. Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally.

History

Publication title

Journal of Neuroimmunology

Volume

360

Article number

360:577719

Number

360:577719

Pagination

1-5

ISSN

0165-5728

Department/School

Tasmanian School of Medicine

Publisher

Elsevier/North-Holland

Place of publication

Amsterdam

Rights statement

Crown Copyright © 2021 Published by Elsevier B.V. All rights reserved.

Repository Status

  • Open

Socio-economic Objectives

Prevention of human diseases and conditions; Preventive medicine